logo
Sign in

ALIDA BIOSCIENCES, INC.

SAN DIEGO, CA · Founded 2020 · Biotech · Private

EpiPlex assay for detecting RNA modifications via proximity barcoding and short-read sequencing

New patent ·
Claim this profile

Follows are private to you and power your alerts

Updated · alidabio.com

Sector
Biotech
Headquarters
SAN DIEGO, CA
Founded
2020
Latest Form D
$7.5M, Jun 2024
Total capital
$20.4M
Federal grants
$8.4M
11 awards · 2021–2025
Rank in peer group#5 of 42
Private capital raised
$12M
3 Form D · last Jun 2024
28 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
8
10 pending · first 2023
Rank in peer group#4 of 42

Capital timeline

20212022202320242025FEDERAL ↑EQUITY ↓Cumulative $20.4M$865K$1.1M$1.1M$1.1M$1.1M$1.1M1st Form D$510K2nd Form D$4M3rd Form D$7.5M
20212022202320242025FEDERAL ↑EQUITY ↓Cumulative $20.4M$1.1M$1.1M$1.1M$1.1M2nd Form D$4M3rd Form D$7.5M

Latest events

  • Federal grantHealth and Human S · Phase II · Pseudouridine detection with single-base resolution in a multiplexed epitranscriptomics assay$1.1M
  • Federal grantHealth and Human S · Phase II · Engineered RNA Modification Recognition$1.1M
  • Federal grantHealth and Human S · Phase II · Engineered RNA Modification Recognition$1.1M
  • Private capital raisedForm D · SEC · 3rd filing$7.5M
  • Federal grantHealth and Human S · Phase II · Rapid NGS Method for Mapping of the Epitranscriptome$1.1M
  • Federal grantHealth and Human S · Phase II · Multiplexed Analysis of the Epitranscriptome$865K
  • Federal grantHealth and Human S · Phase II · Rapid NGS Method for Mapping of the Epitranscriptome$1.1M
  • Private capital raisedForm D · SEC · 2nd filing$4M
  • Private capital raisedForm D · SEC · 1st filing$510K
Show 5 earlier federal awards
  • Federal grantHealth and Human S · Phase I · Engineered RNA Modification Recognition$348K
  • Federal grantHealth and Human S · Phase II · Multiplexed Analysis of the Epitranscriptome$865K
  • Federal grantHealth and Human S · Phase I · Positional Marking of RNA Modifications$260K
  • Federal grantHealth and Human S · Phase I · Rapid NGS Method for Mapping of the Epitranscriptome$260K
  • Federal grantHealth and Human S · Phase I · Multiplexed Analysis of the Epitranscriptome$255K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 42 peers

Line = median

Biotech · Instrument

  • Federal grants#5 · top 12%
  • Granted patents#4 · top 10%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Gudrun StengelResearcherExecutive Officer, DirectorLinked by 7 patents · $4.7M in grants as PI
  • John DrewryDirectorNamed in SEC Form D filings
  • Landon MerrillDirectorNamed in SEC Form D filings
  • Paul ConleyDirectorNamed in SEC Form D filings

What it has protected

USPTO · 8 granted of 18
Show all 18 patent records

Related companies, and why

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .